"The recent approval of VNS as a treatment for
treatment-resistant depression is also important for epilepsy patients,
considering that people with epilepsy also have a high risk of depression and
mood disorders, co-morbidities that can greatly diminish quality of life if
not adequately treated.S.org or call
(800) 332-1000. The patients in the D-02 trial suffered from some of
the most chronic and resistant depressions ever studied. John Rush, MD, Professor and
Vice Chairman for Research, Department of Psychiatry, Betty Jo Hay Chair in
Mental Health, Rosewood Corporation Chair in Biomedical Science, University of
Texas Southwestern Medical Center, Dallas, TX.

supportive answered

Although VNS does not work for everyone, it does offer
psychiatrists and patients the first FDA-approved, safe and effective
long-term treatment option specifically for patients with chronic or recurrent
treatment -resistant depression.

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc. The Company 's initial market was epilepsy, a
disorder characterized by recurrent seizures.

supportive complications

Peer-Reviewed Data Demonstrating Long-Term Safety and Efficacy of Cyberonics' VNS Therapy(TM) for Treatment-Resistant Depression (TRD) Published in Leading Psy

John Rush, MD,
Professor and Vice Chairman for Research, Department of Psychiatry, Betty Jo
Hay Chair in Mental Health, Rosewood Corporation Chair in Biomedical Science ,
University of Texas Southwestern Medical Center, Dallas, TX, et al. Additionally, VNS Therapy was safe and well-tolerated in this
patient population. The differences
in therapeutic effects between the two patient populations were both
statistically significant and clinically important for the patients receiving
adjunctive VNS Therapy as compared to TAU alone."
"Publication of the scientific evidence that was the foundation for FDA
approval in respected peer-reviewed journals such as Biological Psychiatry
facilitates well-informed decisions by psychiatrists and payers and
accomplishment of Cyberonics' mission to improve the lives of people touched
by treatment-resistant depression, " added Robert P.

support4hope moods

"
"Global use of implants overall has doubled since the year 2000, and the
fastest growing category of implants is neurostimulators, devices used to
treat a wide range of CNS disorders , including epilepsy," notes James Cavuoto,
publisher of the Neurotech Business Report. was founded in 1987 to design, develop and market medical
devices for the long-term treatment of epilepsy, depression and other chronic
treatment-resistant disorders using a unique therapy, vagus nerve stimulation
(VNS).com or call
1-877-NOW 4 VNS.7 million
Americans with epilepsy, and an estimated 36 percent of them suffer from
clinical depression."
In addition to the depression associated with epilepsy itself, the mood
disorder is correlated with being either a young female adult, having lower
income , lower rates of employment, more disability, more social concerns and
more side effects due to antiepileptic medication. This is particularly encouraging given the nature of
treatment-resistant depression , a devastating and difficult to treat
condition. The VNS Therapy System delivers
preprogrammed intermittent mild electrical pulses to the vagus nerve in the
patient's neck 24 hours a day.

darkside depressive

In addition to treatment-resistant depression and pharmacoresistant
epilepsy indications, VNS Therapy is at various stages of investigational
clinical studies as a potential treatment for anxiety disorders , Alzheimer's
disease, bulimia and chronic headache/migraine.
"Approximately 30 to 40 percent of patients with epilepsy have seizures
that are not controlled by drugs alone, requiring nonpharmacologic treatment
options like VNS Therapy," said Dr. The VNS Therapy System is also approved for sale as a treatment
for epilepsy in all the European Economic Area, Canada, Australia and other
markets .vnstherapy.
Depression is one of the most under-recognized and under-treated
conditions in people with epilepsy.
"We are extremely pleased with the FDA's approval of VNS Therapy as a
long -term adjunctive treatment in chronic depression.

mood beating

epilepsyfoundation.vnstherapy.

support4hope trapped

Expert neurologists , psychiatrists and
more than 1,000 surgeons from leading medical institutions around the world
are at the forefront of neuromodulation, prescribing and implanting VNS
Therapy. "Cyberonics is clearly a market
leader in the growing neuromodulation market. According to a recent study out of New
York University, depression has a significantly greater negative impact on
quality of life than the seizures themselves., works to ensure that people with seizures are able to participate in all
life experiences , and to prevent, control and cure epilepsy through research,
education, advocacy and services.).

These patients had experienced major depressive disorder for an average of 25
years and had failed to respond or sustain a response to an average of almost
20 different antidepressant treatments, including all available antidepressant
medications, psychotherapy, and in some cases, ECT (electroconvulsive
therapy)." As part of FDA's approval order, Cyberonics is
required to conduct a 450-patient post -market dosing study and a
1,000-patient, five-year patient outcome registry.com or
http://www .

messageboard imagination

In contrast, only one of the
seven acute responders receiving TAU maintained response at 12 months .

coping hanging

HOUSTON, Cyberonics, Inc."
"Once a novel treatment, today VNS Therapy is an important, safe and
effective treatment option for thousands of patients with medically refractory
epilepsy," said Eric Hargis, President and Chief Executive Officer of the
national Epilepsy Foundation . For more information on VNS
Therapy for treatment-resistant depression, including the contraindications ,
warnings and precautions, see the Physician's and Patient's Manuals and other
information at http://www.cyberonics. These articles,
published in the official journal of the Society for Biological Psychiatry,
confirm the association of VNS Therapy with significant antidepressant
benefits that are sustained and/or growing over one year for patients with
chronic or recurrent treatment-resistant depression. The Cyberonics VNS Therapy System was
approved by the FDA on July 16, 1997 for use as an adjunctive therapy in
reducing the frequency of seizures in adults and adolescents over 12 years of
age with partial onset seizures that are refractory to antiepileptic
medications.

depressed proving

(Nasdaq: CYBX)
today announced that Vagus Nerve Stimulation (VNS) Therapy has accumulated
more than 100 ,000 patient years of experience, making it the most widely used
neurostimulation device for the treatment of epilepsy, depression and central
nervous system (CNS) disorders. The Cyberonics VNS Therapy System was
approved by the FDA on July 16, 1997 for use as an adjunctive therapy in
reducing the frequency of seizures in adults and adolescents over 12 years of
age with partial onset seizures that are refractory to antiepileptic
medications. Depression affects more
than a third of all individuals with epilepsy ," said Eric Hargis, president
and CEO of the national Epilepsy Foundation.
The first article , "Vagus Nerve Stimulation (VNS) for Treatment-Resistant
Depression: A Randomized, Controlled Acute Phase Trial" (A.
The third article, "One-Year Comparison of Vagus Nerve Stimulation with
Treatment as Usual for Treatment-Resistant Depression" (Mark S.com or call 1-877-NOW 4 VNS.
Company is headquartered in Houston, Texas and has an office in Brussels,
Belgium.

hanging peers

"The response and remission and sustained long-term benefits realized by
the patients treated with adjunctive VNS Therapy is remarkable, given that
participants in the trials were some of the most treatment-resistant,
depressed patients ever studied, with at least half having been hospitalized
for the disease at least once ," commented Dr.com .

anxiety depressive

The Company's initial market was epilepsy, a
disorder characterized by recurrent seizures." As part of FDA's approval order, Cyberonics is
required to conduct a 450-patient post -market dosing study and a 1,000-
patient, five-year patient outcome registry. For additional information please
visit us at http://www. The FDA decision offers a
significant new treatment option for patients and families affected by these
co-existing conditions.C.

messageboard hanging

VNS Therapy is the first implantable
device-based treatment for depression and the first treatment specifically
developed, studied , approved and labeled for treatment-resistant depression.
Approximately 75 percent of patients reaching end of service elect to continue
with VNS Therapy, further supporting VNS Therapy's safety and effectiveness
record.com .

Although the primary
outcome measure did not reach statistical significance , VNS Therapy was
associated with greater symptom reduction by all primary and secondary
measures and did reach statistical significance in an important secondary
measure. "The VNS studies presented in
these publications provide substantial evidence of a growing benefit of VNS
Therapy over time when other treatments have not worked or have stopped
working.

These are online communities or meeting places which provide information and support to members sharing a common experience such as a condition or disease, or a care-giving role.

voy depression

Stimulation is delivered by the VNS Therapy System(TM), an implantable
generator similar to a cardiac pacemaker.

New FDA Approval for VNS Therapy Provides Potential 2-in -1 Treatment for People with Epilepsy

Twenty-seven percent of
patients receiving adjunctive VNS Therapy experienced response compared to 13%
of patients receiving TAU.
The publication of peer-reviewed data follows FDA approval of VNS Therapy
as an adjunctive long-term treatment of chronic or recurrent depression for
patients 18 years of age or older who are experiencing a major depressive
episode and have not had an adequate response to four or more adequate
antidepressant treatments .
VNS Therapy is the first implantable device-based treatment for depression
and the first treatment specifically developed, studied, approved and labeled
for treatment-resistant depression .

complications ptsd

"Years of clinical use and more than
100,000 patient years of experience have shown that VNS Therapy is a valuable
long-term treatment option for pharmacoresistant epilepsy with benefits to
patients that improve over time. Stimulation is delivered by the VNS Therapy System(TM), an implantable
generator similar to a cardiac pacemaker.cyberonics.

proving coping

The VNS Therapy System delivers
preprogrammed intermittent mild electrical pulses to the vagus nerve in the
patient's neck 24 hours a day. Epilepsy is the second most
prevalent neurological disorder. WASHINGTON, The U. More than twice as many patients receiving
adjunctive VNS Therapy experienced remission. The VNS Therapy System is also approved for sale as a treatment
for epilepsy in all the European Economic Area, Canada, Australia and other
markets.

trapped darkside

Cyberonics' VNS Therapy Surpasses 100 000 Patient Years of Experience

To date, more than 32,000 epilepsy patients in 24 countries have
accumulated over 100,000 patient years of experience using VNS Therapy. Vagus Nerve Stimulation entails
having a small electrical device implanted in the patient's chest and
connected to the vagus nerve at the side of the neck.

The Epilepsy Foundation, with national offices in metropolitan Washington,
D. Epilepsy is the second most
prevalent neurological disorder.

answered depressed

Eight years after FDA approval as an
adjunctive therapy used to reduce the frequency of seizures in adults and
adolescents over 12 years of age with partial onset seizures that are
refractory to antiepileptic medications, VNS Therapy has been used to treat
more than 32,000 patients worldwide. Three Peer-Reviewed Articles Published in Biological Psychiatry

HOUSTON, Cyberonics, Inc. These two
groups were comparable in terms of baseline characteristics . Response was maintained
long-term for 73% of the VNS treated patients. ("Skip") Cummins,
Cyberonics ' Chairman of the Board and Chief Executive Officer.

depressed supportive

The 100,000 patient years milestone comes on the heels of FDA approval of
VNS Therapy as an adjunctive long-term treatment of chronic or recurrent
depression for patients 18 years of age or older who are experiencing a major
depressive episode and have not had an adequate response to four or more
adequate antidepressant treatments. Manufactured by
Cyberonics, the device delivers small bursts of electricity at various
intervals to prevent a seizure from happening. Twenty-seven percent of patients with chronic or
recurrent TRD experienced response, and 16% of patients experienced remission. In addition to treatment-resistant
depression and pharmacoresistant epilepsy indications, VNS Therapy is at
various stages of investigational clinical studies as a potential treatment
for anxiety disorders, Alzheimer's disease, bulimia and chronic
headache/migraine. To date, more than 32,000 epilepsy patients in 24 countries have
accumulated over 100,000 patient years of experience using VNS Therapy. For additional information please visit us at
http://www.

ptsd trapped

James W.
VNS Therapy is at various levels of investigational clinical study as a
potential treatment for anxiety disorders, Alzheimer's disease, chronic
headache/migraine and bulimia. It has become a common method
of treatment for epilepsy since its approval by the FDA in 1997. In this study (n=205), treatment with increased doses of adjunctive VNS
Therapy over a one-year period of time resulted in statistically significant
and clinically meaningful reductions in depressive symptoms across all primary
and secondary measures.cyberonics.

Message boards, mailing lists, chat rooms and moderated forums may be found here.

imagination answered

"Yet, it is greatly under-
diagnosed in people with seizure disorders.),
evaluated two similar groups of patients with treatment-resistant depression,
the D-02 group (n=205) who received adjunctive VNS Therapy with treatment as
usual (TAU) and the D-04 study group receiving TAU alone (n=124).
The VNS Therapy System has been approved for sale in the European Economic
Area and in Canada as a treatment for depression in patients with
treatment-resistant or treatment-intolerant major depressive episodes,
including unipolar depression and bipolar disorder (manic depression) since
2001.

complications messageboard

The VNS Therapy System has been approved for sale in the European Economic
Area and in Canada as a treatment for depression in patients with treatment-
resistant or treatment-intolerant major depressive episodes, including
unipolar depression and bipolar disorder (manic depression) since 2001. The Company is headquartered in Houston, Texas
and has an office in Brussels, Belgium. Food and Drug
Administration's recent approval of Vagus Nerve Stimulation Therapy for
treatment of chronic depression provides a novel single-treatment option for
two major symptoms suffered by people with epilepsy. VNS Therapy, a form of treatment in use to control
seizures, now offers the potential of making life better for people with
epilepsy by mitigating both the seizures and the accompanying mood disorder. George, MD,
Distinguished Professor of Psychiatry, Radiology and Neurosciences, Director,
MUSC Center for Advanced Imaging Research, Director, Brain Stimulation
Laboratory, Medical University of South Carolina, Charleston, SC, et al. For more information on
VNS Therapy for treatment-resistant depression, including the
contraindications , warnings and precautions, see the Physician's and Patient's
Manuals and other information at http: //www.

depressed messageboard

The VNS Therapy System was approved by the FDA on July 15, 2005 "as an
adjunctive long -term treatment for chronic or recurrent depression for
patients 18 years of age and older who are experiencing a major depressive
episode and have not had an adequate response to four or more adequate
antidepressant treatments.

John Rush, MD, et
al. A.

sad support4hope

"

ABOUT VNS THERAPY AND CYBERONICS
Cyberonics, Inc.), reports
outcomes from a ten-week, randomized-control, acute phase study with 235
patients in 21 sites. Importantly, 73% of patients experiencing response at three months,
maintained response after one year of treatment with adjunctive VNS Therapy.

imagination beating

Wheless , Professor and Chief of
Pediatric Neurology, Le Bonheur Chair in Pediatric Neurology at the University
of Tennessee Health Science Center. There are 2. The Epilepsy Foundation has
several initiatives in place meant to address and combat this psychological
impact of epilepsy.
For more information on VNS Therapy, or to learn more about programs the
Epilepsy Foundation has in place, visit http: //www. (Nasdaq: CYBX)
today announced that peer-reviewed data from the D-02 pivotal study including
the randomized, controlled acute phase trial, one-year open study and one-year
comparison of the D-02 patients treated with VNS plus treatments-as-usual and
the D-04 patients treated only with treatments -as-usual (no VNS) have been
published in the September 1 issue of Biological Psychiatry.
The second article reports the 12-month outcomes in the naturalistic
long-term phase of the study, "Effects of 12 Months of Vagus Nerve Stimulation
in Treatment-Resistant Depression: A Naturalistic Study" (A. was founded in 1987 to design, develop and market medical
devices for the long-term treatment of epilepsy, depression and other chronic
treatment-resistant disorders using a unique therapy, vagus nerve stimulation
(VNS).
The VNS Therapy System was approved by the FDA on July 15, 2005 "as an
adjunctive long-term treatment for chronic or recurrent depression for
patients 18 years of age and older who are experiencing a major depressive
episode and have not had an adequate response to four or more adequate
antidepressant treatments.